<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, <z:chebi fb="0" ids="28901">busulfan</z:chebi>, and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (TBC) as the preparative regimen for treatment of advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts with or without transformation) or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) past first remission </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> evaluable patients engrafted and had complete donor chimerism </plain></SENT>
<SENT sid="2" pm="."><plain>A grade 3-4 regimen-related toxicity occurred in eight (13%) patients, and a diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was the only independent risk factor for grade 3-4 regimen-related toxicity (hazard ratio 9.25, P = 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>Day-100 treatment-related mortality (TRM) was 19% </plain></SENT>
<SENT sid="4" pm="."><plain>Poor-prognosis cytogenetics increased the risk of day-100 TRM (hazard ratio 11.4, P = 0.003), and use of tacrolimus for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> prophylaxis reduced the risk of day-100 TRM (hazard ratio 0.13, P = 0.027) </plain></SENT>
<SENT sid="5" pm="."><plain>For <z:hpo ids='HP_0000001'>all</z:hpo> patients, the three-year relapse rate was 43% (95% CI, 28%-58%) </plain></SENT>
<SENT sid="6" pm="."><plain>Refractoriness to conventional induction chemotherapy prior to transplantation was an independent risk factor for relapse (hazard ratio 10.8, P = 0.02) </plain></SENT>
<SENT sid="7" pm="."><plain>Three-year survival was 26% (95% CI, 14%-37%); survival rates were 29% for those transplanted for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in second remission, 31% transplanted for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in relapse, and 17% with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and there were no independent risk factors for survival </plain></SENT>
<SENT sid="8" pm="."><plain>TBC is an active preparative regimen for advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> appeared to have a higher risk of toxicity and early mortality, and alternative preparative regimens should be considered for these patients </plain></SENT>
</text></document>